container_end_page E544
container_issue 9
container_start_page E542
container_title American journal of hematology
container_volume 92
creator Helber, Margaret J.
Moore, Jeremiah E.
Williams, AnnaLynn M.
Meacham, Philip J.
Rothberg, Paul G.
Zent, Clive S.
description
doi_str_mv 10.1002/ajh.24795
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1926445599</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1926445599</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3885-fa910b18995f9ca70d7c5b731dd008be2a34cd8171fcfa93dcad1f0d3cc495d53</originalsourceid><addsrcrecordid>eNp1kM9LwzAUgIMobk4P_gMy8OSh20uTtMlxDHWTgRc9hzQ_WEe71qRF-t8b7fTm6T0eH9-DD6FbDAsMkC7VYb9IaS7YGZpiEFnCM5aeoymQDMcdxARdhXAAwJhyuESTlDNK8oxNEWwL33flsSzm3d561Q5z1_h5NdTtvmkrFWqlh67Up0utrtGFU1WwN6c5Q-9Pj2_rTbJ7fd6uV7tEE85Z4pTAUGAuBHNCqxxMrlmRE2wMAC9sqgjVhuMcOx1ZYrQy2IEhWlPBDCMzdD96W9989DZ08tD0_hhfSizSjFLGhIjUw0hp34TgrZOtL2vlB4lBfreRsY38aRPZu5OxL2pr_sjfGBFYjsBnWdnhf5NcvWxG5Rc8u222</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1926445599</pqid></control><display><type>article</type><title>Ibrutinib therapy for lymphoplasmacytic lymphoma</title><source>MEDLINE</source><source>Wiley Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><creator>Helber, Margaret J. ; Moore, Jeremiah E. ; Williams, AnnaLynn M. ; Meacham, Philip J. ; Rothberg, Paul G. ; Zent, Clive S.</creator><creatorcontrib>Helber, Margaret J. ; Moore, Jeremiah E. ; Williams, AnnaLynn M. ; Meacham, Philip J. ; Rothberg, Paul G. ; Zent, Clive S.</creatorcontrib><identifier>ISSN: 0361-8609</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/ajh.24795</identifier><identifier>PMID: 28543765</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adult ; Agammaglobulinaemia Tyrosine Kinase ; Aged ; Aged, 80 and over ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Female ; Humans ; Immunoglobulin M - blood ; Kidney Failure, Chronic - etiology ; Lymphoma ; Male ; Middle Aged ; Molecular Targeted Therapy ; Neoplasm Proteins - antagonists &amp; inhibitors ; Paraproteins - analysis ; Protein-Tyrosine Kinases - antagonists &amp; inhibitors ; Pyrazoles - adverse effects ; Pyrazoles - pharmacology ; Pyrazoles - therapeutic use ; Pyrimidines - adverse effects ; Pyrimidines - pharmacology ; Pyrimidines - therapeutic use ; Salvage Therapy ; Targeted cancer therapy ; Treatment Outcome ; Waldenstrom Macroglobulinemia - complications ; Waldenstrom Macroglobulinemia - drug therapy</subject><ispartof>American journal of hematology, 2017-09, Vol.92 (9), p.E542-E544</ispartof><rights>2017 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3885-fa910b18995f9ca70d7c5b731dd008be2a34cd8171fcfa93dcad1f0d3cc495d53</citedby><cites>FETCH-LOGICAL-c3885-fa910b18995f9ca70d7c5b731dd008be2a34cd8171fcfa93dcad1f0d3cc495d53</cites><orcidid>0000-0002-7042-5851 ; 0000-0001-6099-3313</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fajh.24795$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fajh.24795$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28543765$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Helber, Margaret J.</creatorcontrib><creatorcontrib>Moore, Jeremiah E.</creatorcontrib><creatorcontrib>Williams, AnnaLynn M.</creatorcontrib><creatorcontrib>Meacham, Philip J.</creatorcontrib><creatorcontrib>Rothberg, Paul G.</creatorcontrib><creatorcontrib>Zent, Clive S.</creatorcontrib><title>Ibrutinib therapy for lymphoplasmacytic lymphoma</title><title>American journal of hematology</title><addtitle>Am J Hematol</addtitle><subject>Adult</subject><subject>Agammaglobulinaemia Tyrosine Kinase</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Immunoglobulin M - blood</subject><subject>Kidney Failure, Chronic - etiology</subject><subject>Lymphoma</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Molecular Targeted Therapy</subject><subject>Neoplasm Proteins - antagonists &amp; inhibitors</subject><subject>Paraproteins - analysis</subject><subject>Protein-Tyrosine Kinases - antagonists &amp; inhibitors</subject><subject>Pyrazoles - adverse effects</subject><subject>Pyrazoles - pharmacology</subject><subject>Pyrazoles - therapeutic use</subject><subject>Pyrimidines - adverse effects</subject><subject>Pyrimidines - pharmacology</subject><subject>Pyrimidines - therapeutic use</subject><subject>Salvage Therapy</subject><subject>Targeted cancer therapy</subject><subject>Treatment Outcome</subject><subject>Waldenstrom Macroglobulinemia - complications</subject><subject>Waldenstrom Macroglobulinemia - drug therapy</subject><issn>0361-8609</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM9LwzAUgIMobk4P_gMy8OSh20uTtMlxDHWTgRc9hzQ_WEe71qRF-t8b7fTm6T0eH9-DD6FbDAsMkC7VYb9IaS7YGZpiEFnCM5aeoymQDMcdxARdhXAAwJhyuESTlDNK8oxNEWwL33flsSzm3d561Q5z1_h5NdTtvmkrFWqlh67Up0utrtGFU1WwN6c5Q-9Pj2_rTbJ7fd6uV7tEE85Z4pTAUGAuBHNCqxxMrlmRE2wMAC9sqgjVhuMcOx1ZYrQy2IEhWlPBDCMzdD96W9989DZ08tD0_hhfSizSjFLGhIjUw0hp34TgrZOtL2vlB4lBfreRsY38aRPZu5OxL2pr_sjfGBFYjsBnWdnhf5NcvWxG5Rc8u222</recordid><startdate>201709</startdate><enddate>201709</enddate><creator>Helber, Margaret J.</creator><creator>Moore, Jeremiah E.</creator><creator>Williams, AnnaLynn M.</creator><creator>Meacham, Philip J.</creator><creator>Rothberg, Paul G.</creator><creator>Zent, Clive S.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><orcidid>https://orcid.org/0000-0002-7042-5851</orcidid><orcidid>https://orcid.org/0000-0001-6099-3313</orcidid></search><sort><creationdate>201709</creationdate><title>Ibrutinib therapy for lymphoplasmacytic lymphoma</title><author>Helber, Margaret J. ; Moore, Jeremiah E. ; Williams, AnnaLynn M. ; Meacham, Philip J. ; Rothberg, Paul G. ; Zent, Clive S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3885-fa910b18995f9ca70d7c5b731dd008be2a34cd8171fcfa93dcad1f0d3cc495d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Agammaglobulinaemia Tyrosine Kinase</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Immunoglobulin M - blood</topic><topic>Kidney Failure, Chronic - etiology</topic><topic>Lymphoma</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Molecular Targeted Therapy</topic><topic>Neoplasm Proteins - antagonists &amp; inhibitors</topic><topic>Paraproteins - analysis</topic><topic>Protein-Tyrosine Kinases - antagonists &amp; inhibitors</topic><topic>Pyrazoles - adverse effects</topic><topic>Pyrazoles - pharmacology</topic><topic>Pyrazoles - therapeutic use</topic><topic>Pyrimidines - adverse effects</topic><topic>Pyrimidines - pharmacology</topic><topic>Pyrimidines - therapeutic use</topic><topic>Salvage Therapy</topic><topic>Targeted cancer therapy</topic><topic>Treatment Outcome</topic><topic>Waldenstrom Macroglobulinemia - complications</topic><topic>Waldenstrom Macroglobulinemia - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Helber, Margaret J.</creatorcontrib><creatorcontrib>Moore, Jeremiah E.</creatorcontrib><creatorcontrib>Williams, AnnaLynn M.</creatorcontrib><creatorcontrib>Meacham, Philip J.</creatorcontrib><creatorcontrib>Rothberg, Paul G.</creatorcontrib><creatorcontrib>Zent, Clive S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Helber, Margaret J.</au><au>Moore, Jeremiah E.</au><au>Williams, AnnaLynn M.</au><au>Meacham, Philip J.</au><au>Rothberg, Paul G.</au><au>Zent, Clive S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ibrutinib therapy for lymphoplasmacytic lymphoma</atitle><jtitle>American journal of hematology</jtitle><addtitle>Am J Hematol</addtitle><date>2017-09</date><risdate>2017</risdate><volume>92</volume><issue>9</issue><spage>E542</spage><epage>E544</epage><pages>E542-E544</pages><issn>0361-8609</issn><eissn>1096-8652</eissn><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>28543765</pmid><doi>10.1002/ajh.24795</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-7042-5851</orcidid><orcidid>https://orcid.org/0000-0001-6099-3313</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0361-8609
ispartof American journal of hematology, 2017-09, Vol.92 (9), p.E542-E544
issn 0361-8609
1096-8652
language eng
recordid cdi_proquest_journals_1926445599
source MEDLINE; Wiley Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content
subjects Adult
Agammaglobulinaemia Tyrosine Kinase
Aged
Aged, 80 and over
Antineoplastic Agents - adverse effects
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Female
Humans
Immunoglobulin M - blood
Kidney Failure, Chronic - etiology
Lymphoma
Male
Middle Aged
Molecular Targeted Therapy
Neoplasm Proteins - antagonists & inhibitors
Paraproteins - analysis
Protein-Tyrosine Kinases - antagonists & inhibitors
Pyrazoles - adverse effects
Pyrazoles - pharmacology
Pyrazoles - therapeutic use
Pyrimidines - adverse effects
Pyrimidines - pharmacology
Pyrimidines - therapeutic use
Salvage Therapy
Targeted cancer therapy
Treatment Outcome
Waldenstrom Macroglobulinemia - complications
Waldenstrom Macroglobulinemia - drug therapy
title Ibrutinib therapy for lymphoplasmacytic lymphoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T15%3A02%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ibrutinib%20therapy%20for%20lymphoplasmacytic%20lymphoma&rft.jtitle=American%20journal%20of%20hematology&rft.au=Helber,%20Margaret%20J.&rft.date=2017-09&rft.volume=92&rft.issue=9&rft.spage=E542&rft.epage=E544&rft.pages=E542-E544&rft.issn=0361-8609&rft.eissn=1096-8652&rft_id=info:doi/10.1002/ajh.24795&rft_dat=%3Cproquest_cross%3E1926445599%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1926445599&rft_id=info:pmid/28543765&rfr_iscdi=true